Insight Molecular Diagnostics Inc. SEC filings IMDX
Insight Molecular Diagnostics Inc. has 688 filings in SEC EDGAR's recent list, going back to May 14, 2015. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 21, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 7, 2025 | — |
| CORRESP | Letter to the SEC | Apr 4, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2025 | — |
| D | Filing | Feb 24, 2025 | — |
| EFFECT | Filing | Oct 21, 2024 | — |
| CORRESP | Letter to the SEC | Oct 21, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 17, 2024 | — |
| D | Filing | Oct 8, 2024 | — |
| EFFECT | Filing | Aug 7, 2024 | — |
| CORRESP | Letter to the SEC | Aug 7, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2024 | — |
| EFFECT | Filing | May 22, 2024 | — |
| CORRESP | Letter to the SEC | May 21, 2024 | — |
| UPLOAD | Letter from the SEC | May 14, 2024 | — |
| D | Filing | Apr 25, 2024 | — |
| NT 10-K | Filing | Apr 1, 2024 | Dec 31, 2023 |
| DEFR14A | Filing | May 22, 2023 | — |
| NT 10-K | Filing | Apr 3, 2023 | Dec 31, 2022 |
| EFFECT | Filing | Jul 29, 2021 | — |
| CORRESP | Letter to the SEC | Jul 26, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2021 | — |
| EFFECT | Filing | Jun 8, 2021 | — |
| CORRESP | Letter to the SEC | Jun 4, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2021 | — |
| CORRESP | Letter to the SEC | May 28, 2021 | — |
| D | Filing | Apr 29, 2021 | — |
| D | Filing | Mar 8, 2021 | — |
| CERT | Filing | Mar 5, 2021 | — |
| 25 | Filing | Mar 5, 2021 | — |
| 8-A12B | Filing | Mar 1, 2021 | — |
| EFFECT | Filing | Aug 20, 2020 | — |
| CORRESP | Letter to the SEC | Aug 17, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 7, 2020 | — |
| UPLOAD | Letter from the SEC | May 26, 2020 | — |
| CORRESP | Letter to the SEC | May 18, 2020 | — |
| PRER14A | Filing | May 18, 2020 | — |
| UPLOAD | Letter from the SEC | May 12, 2020 | — |
| CORRESP | Letter to the SEC | Apr 28, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 19, 2020 | — |
| D | Filing | Feb 11, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 6, 2020 | — |
| EFFECT | Filing | Jun 18, 2019 | — |
| CORRESP | Letter to the SEC | Jun 17, 2019 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 18, 2017 | — |
| EFFECT | Filing | Oct 16, 2017 | — |
| CORRESP | Letter to the SEC | Oct 12, 2017 | — |
| EFFECT | Filing | Oct 20, 2016 | — |
| UPLOAD | Letter from the SEC | Oct 11, 2016 | — |
| D | Filing | Sep 9, 2016 | — |
| CT ORDER | Filing | Jun 24, 2016 | — |
| CT ORDER | Filing | Jan 28, 2016 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2015 | — |
| 10-12B/A | Oncocyte corporation 10-12ba no. 2 12-29-2015 | Dec 29, 2015 | — |
| CORRESP | Letter to the SEC | Dec 28, 2015 | — |
| CORRESP | Letter to the SEC | Dec 28, 2015 | — |
| CERTNYS | Auto-generated paper document | Dec 28, 2015 | — |
| 10-12B/A | Oncocyte corporation 10-12b/a 12-21-2015 | Dec 21, 2015 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2015 | — |
| RW | Oncocyte corporation rw 11-23-2015 | Nov 23, 2015 | — |
| 10-12B | Oncocyte corporation 10-12b 11-23-2015 | Nov 23, 2015 | — |
| UPLOAD | Letter from the SEC | Nov 5, 2015 | — |
| D | Filing | Oct 15, 2015 | — |
| 10-12G | Oncocyte corporation 10-12g 10-7-2015 | Oct 7, 2015 | — |
| D | Filing | May 14, 2015 | — |
Showing 65 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IMDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Nashville, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1642380
- Former names
- OncoCyte Corp (until Jun 17, 2025); Oncocyte Corp (until Jun 17, 2025)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.